Pentoxifylline does not improve outcome in a murine model for the multiple-organ dysfunction syndrome
Authors:
- 15 February 2005
- journal article
- research article
- Published by Springer Nature in Intensive Care Medicine
- Vol. 31 (5) , 701-708
Abstract
To investigate the effects of pentoxifylline (PTX) administration in a murine model for the multiple-organ dysfunction syndrome (MODS). Prospective double-blind randomized animal study in a university research laboratory. Sixty C57BL/6 mice were given an aseptic intraperitoneal injection of lipopolysaccharide followed after 6 days by zymosan (day 0) at a dose of either 0.9 or 1.0 mg/g body weight. Starting on day 0 mice were administered PTX at a dose of 80 mg/kg body weight or saline per os every 8 h. On day 17 surviving animals were killed, and their liver, lungs, spleen, and kidneys were collected. Mortality, course of body temperature, body weight, and macroscopic lung damage were similar between zymosan-treated groups. Administration of PTX did not significantly alter survival, body temperature, body weight, or macroscopic lung damage. In addition, there were no significant differences in organ weights between mice that received PTX and mice that received PBS. Although PTX inhibited the lipopolysaccharide-induced increase in tumor necrosis factor α and interleukin 6 expression (but not interleukin 1β expression) at both mRNA and protein level in a murine macrophage cell line, tumor necrosis factor α mRNA expression in the livers of PTX-treated mice was not significantly inhibited. The results reported here do not support the hypothesis that PTX improves outcome in zymosan-induced multiple-organ dysfunction in mice.Keywords
This publication has 43 references indexed in Scilit:
- Extrinsic allergic alveolitis: inhibitory effects of pentoxifylline on cytokine production by alveolar macrophagesAnnals of Allergy, Asthma & Immunology, 2004
- Effects of Pentoxifylline on Inflammatory Cytokine Expression and Acute Pleuropneumonia in SwineImmunobiology, 2002
- The Phosphodiesterase Inhibitors Pentoxifylline and Rolipram Suppress Macrophage Activation and Nitric Oxide Production in Vitro and in VivoClinical Immunology, 2001
- Beneficial effects of tempol, a membrane-permeable radical scavenger, on the multiple organ failure induced by zymosan in the ratCritical Care Medicine, 2001
- Dextran Sulfate Sodium-Induced Colonic Histopathology, but not Altered Epithelial Ion Transport, Is Reduced by Inhibition of Phosphodiesterase ActivityThe American Journal of Pathology, 2000
- Toward a theory regarding the pathogenesis of the systemic inflammatory response syndromeCritical Care Medicine, 1996
- VOLATILE ANESTHETIC MODULATION OF LUNG INJURY AND OUTCOME IN A MURINE MODEL OF MULTIPLE ORGAN DYSFUNCTION SYNDROMEShock, 1995
- THE EFFECTS OF ORAL PENTOXIFYLLINE ON THE CYTOKINE RELEASE SYNDROME DURING INDUCTIVE OKT3Transplantation, 1994
- PentoxifyllineDrugs, 1987
- Clinical Pharmacology of Pentoxifylline With Special Reference to Its Hemorrheologic Effect for the Treatment of Intermittent ClaudicationThe Journal of Clinical Pharmacology, 1985